Table 7 summarizes drug interactions that affect the exposure of Balversa or serum phosphate level and their clinical management.
Table 8 summarizes the effect of Balversa on other drugs and their clinical management.
from FDA,2024.01
Balversa is specifically designed for patients with advanced urothelial carcinom···【more】
Release date:2024-08-28Recommended:138
Balversais an oral anti-tumor drug for the treatment of urothelial carcinoma wit···【more】
Release date:2024-08-28Recommended:119
Balversa is a new anti-cancer drug targeting FGFR, targeting urothelial carcinom···【more】
Release date:2024-08-28Recommended:155